Goldman Sachs Says Curing Diseases May Not Be Economically Viable

Goldman Sachs Says Curing Diseases May Not Be Economically Viable, by Natali Mis.

A leaked report has stated what many in the health industry have whispered privately; there is a lot less money in curing people than in long-term management of disease.

The issue is brought into focus by the possibility of a gene therapy that could soon cure a large variety of genetic conditions by changing individual units of DNA. …

Richter points to the sofosbuvir treatment of hepatitis C marketed by Gilead Sciences. In 2015 this brought the company $12.5 billion, mostly in the United States, as people suffering liver damage from the virus rushed to take up the new drug. However, the therapy cures most patients so thoroughly they’re finished treatment within 12 weeks. Better still from a social perspective, but worse for profits, once treated people no longer transmit the virus, preventing new infections. This year Richter expects American sales to fall to less than $4 billion.